Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients.

Abstract

Gemcitabine/carboplatin chemotherapy commonly induces myelosuppression, including neutropenia, leukopenia, and thrombocytopenia. Predicting patients at risk of these adverse drug reactions (ADRs) and adjusting treatments accordingly is a long-term goal of personalized medicine. This study used whole-genome sequencing (WGS) of blood samples from 96 gemcitabine/carboplatin-treated non-small cell lung cancer (NSCLC) patients and gene network modules for predicting myelosuppression. Association of genetic variants in PLINK found 4594, 5019, and 5066 autosomal SNVs/INDELs with p ≤ 1 × 10-3 for neutropenia, leukopenia, and thrombocytopenia, respectively. Based on the SNVs/INDELs we identified the toxicity module, consisting of 215 unique overlapping genes inferred from MCODE-generated gene network modules of 350, 345, and 313 genes, respectively. These module genes showed enrichment for differentially expressed genes in rat bone marrow, human bone marrow, and human cell lines exposed to carboplatin and gemcitabine (p < 0.05). Then using 80% of the patients as training data, random LASSO reduced the number of SNVs/INDELs in the toxicity module into a feasible prediction model consisting of 62 SNVs/INDELs that accurately predict both the training and the test (remaining 20%) data with high (CTCAE 3-4) and low (CTCAE 0-1) maximal myelosuppressive toxicity completely, with the receiver-operating characteristic (ROC) area under the curve (AUC) of 100%. The present study shows how WGS, gene network modules, and random LASSO can be used to develop a feasible and tested model for predicting myelosuppressive toxicity. Although the proposed model predicts myelosuppression in this study, further evaluation in other studies is required to determine its reproducibility, usability, and clinical effect.

• Authors: Niclas Björn, Tejaswi Venkata Satya Badam, Rapolas Spalinskas, Eva Brandén, Hirsh Koyi, Rolf Lewensohn, Luigi De Petris, Zelmina Lubovac-Pilav, Pelin Sahlén, Joakim Lundeberg, Mika Gustafsson, Henrik Gréen
• Journal: NPJ systems biology and applications (NPJ Syst Biol Appl) Vol. 6 Issue 1 Pg. 25 (08 24 2020) ISSN: 2056-7189 [Electronic] England
• PMID: 32839457 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Deoxycytidine
• Carboplatin
• Gemcitabine

Topics

• Bone Marrow (drug effects, immunology)
• Carboplatin (adverse effects, therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy, genetics, immunology)
• Deoxycytidine (adverse effects, analogs & derivatives, therapeutic use)
• Gene Regulatory Networks (drug effects)
• Humans
• Lung Neoplasms (drug therapy, genetics, immunology)
• Whole Genome Sequencing
• Gemcitabine